临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
progression-free survival comparison,252 252
DNA microarray colon cancer,343–344 344
cytogenetics confluence in hematological cancers,323 323
hepatocellular carcinoma,344–345 345
interferon-α gene expression response,530–531 531
ovarian cancer,342–343 343
subgroup stratification,87–88 88
Docetaxel Gradishar study,224–225 225
Dose animal studies for estimation,13–15,18 18
escalation and Moore schema,41–43 43
modification for adverse events,420–423 423
units expressed in terms of body surface area,35–36 36
Dose-limiting toxicity (DLT),18,42–43 43
Double-blind study,112 112
Double-dummy study,112 112
Doxorubicin resistance,78 78
Drug Amendments Act of 1962,580 580
Drug origins animal models,11–15 15
high-throughput screening,7 7